Performa Ltd US LLC Has $39,000 Stock Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Performa Ltd US LLC raised its stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 112.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,000 shares of the company’s stock after acquiring an additional 3,175 shares during the period. Maravai LifeSciences comprises about 0.0% of Performa Ltd US LLC’s investment portfolio, making the stock its 23rd largest position. Performa Ltd US LLC’s holdings in Maravai LifeSciences were worth $39,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of the stock. 12 West Capital Management LP lifted its stake in shares of Maravai LifeSciences by 92.2% during the third quarter. 12 West Capital Management LP now owns 6,463,111 shares of the company’s stock valued at $64,631,000 after acquiring an additional 3,101,275 shares during the period. Braidwell LP lifted its stake in shares of Maravai LifeSciences by 120.3% during the third quarter. Braidwell LP now owns 3,974,857 shares of the company’s stock valued at $39,749,000 after acquiring an additional 2,170,157 shares during the period. Mackenzie Financial Corp lifted its stake in shares of Maravai LifeSciences by 39.0% during the third quarter. Mackenzie Financial Corp now owns 4,930,841 shares of the company’s stock valued at $48,667,000 after acquiring an additional 1,384,455 shares during the period. Pacer Advisors Inc. lifted its stake in shares of Maravai LifeSciences by 37.8% during the fourth quarter. Pacer Advisors Inc. now owns 2,955,230 shares of the company’s stock valued at $19,357,000 after acquiring an additional 810,957 shares during the period. Finally, AQR Capital Management LLC lifted its stake in shares of Maravai LifeSciences by 80.5% during the third quarter. AQR Capital Management LLC now owns 1,749,003 shares of the company’s stock valued at $17,210,000 after acquiring an additional 779,838 shares during the period. 50.25% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on MRVI shares. Craig Hallum assumed coverage on Maravai LifeSciences in a research note on Wednesday, April 10th. They set a “buy” rating and a $15.00 price target on the stock. Royal Bank of Canada increased their price objective on shares of Maravai LifeSciences from $12.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, February 23rd. Stifel Nicolaus lowered their target price on shares of Maravai LifeSciences from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, February 23rd. Finally, Robert W. Baird raised their target price on shares of Maravai LifeSciences from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Thursday. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.44.

Maravai LifeSciences Price Performance

Maravai LifeSciences stock traded up $0.44 during midday trading on Thursday, reaching $9.31. 799,513 shares of the stock were exchanged, compared to its average volume of 2,458,451. The company has a debt-to-equity ratio of 0.70, a quick ratio of 7.41 and a current ratio of 8.00. Maravai LifeSciences Holdings, Inc. has a 52 week low of $4.52 and a 52 week high of $16.62. The firm has a market cap of $2.34 billion, a PE ratio of -9.86 and a beta of 0.03. The company’s fifty day moving average is $8.09 and its 200-day moving average is $6.73.

Maravai LifeSciences (NASDAQ:MRVI) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Maravai LifeSciences had a negative return on equity of 1.31% and a negative net margin of 41.19%. The company had revenue of $74.14 million during the quarter, compared to analysts’ expectations of $62.99 million. On average, sell-side analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.15 EPS for the current year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.